Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Roivant Sciences Ltd. Director's Dealing 2021

Oct 1, 2021

30587_dirs_2021-10-01_89d0094a-7fdf-4560-800a-1b9560e3e160.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2021-10-01

Reporting Person: Machado Patrick (Director)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $5.19 2026-10-19 Common Shares (170167) Direct
Stock Option (Right to Buy) $7.43 2027-12-19 Common Shares (109732) Direct
Stock Option (Right to Buy) $11.19 2029-01-21 Common Shares (109732) Direct
Stock Option (Right to Buy) $12.68 2030-01-19 Common Shares (109732) Direct
Stock Option (Right to Buy) $10.00 2031-05-01 Common Shares (109732) Direct

Footnotes

F1: Award of stock options to purchase Common Shares that is fully vested.

F2: Award of stock options to purchase Common Shares with a vesting commencement date of November 30, 2018.

F3: Award of stock options to purchase Common Shares with a vesting commencement date of November 30, 2019.

F4: Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019.

F5: Awards of stock options to purchase Common Shares vest and become exercisable (i) 33% on the first anniversary of the applicable vesting commencement date and (ii) in 24 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.